Anthracycline Cardiotoxicity: From Bench to Bedside
Top Cited Papers
- 1 August 2008
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (22), 3777-3784
- https://doi.org/10.1200/jco.2007.14.9401
Abstract
Anthracyclines remain among the most widely prescribed and effective anticancer agents. Unfortunately, life-threatening cardiotoxicity continues to compromise their usefulness. Despite more than four decades of investigation, the pathogenic mechanisms responsible for anthracycline cardiotoxicity have not been completely elucidated. In addition, new drugs and combination therapies often exacerbate the toxicity. The First International Workshop on Anthracycline Cardiotoxicity, held in fall 2006, in Como, Italy, focused on the state-of-the-art knowledge and discussed the research needed to address the cardiotoxicity of these drugs. Here, we incorporate these discussions into the framework of a broader review of preclinical and clinical issues.Keywords
This publication has 111 references indexed in Scilit:
- American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late EffectsJournal of Clinical Oncology, 2007
- Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and managementExpert Opinion on Pharmacotherapy, 2007
- Anthracycline-induced phospholipase A2 inhibitionCardiovascular Toxicology, 2007
- Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategiesBritish Journal of Haematology, 2005
- N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?Clinical Chemistry, 2005
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in AdultsJournal of Clinical Oncology, 2004
- Enalapril to Prevent Cardiac Function Decline in Long-Term Survivors of Pediatric Cancer Exposed to AnthracyclinesJournal of Clinical Oncology, 2004
- Antioxidants and Cancer Therapy: A Systematic ReviewJournal of Clinical Oncology, 2004